Rules/misleading presentation/US-MIS-007

No overstating the generalizability of a single study's experience

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

A study may not be presented in a way implying it reflects broader or more general clinical experience than it actually represents.

Check

Compare the study's actual scope/size/population to how it is characterized in the ad's presentation.

Escalate when

Whether the presentation overstates generalizability is a matter of degree.

Where this comes from

21 CFR 202.1(e)(6)(v). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…sentation or suggestion that a drug is safer than it has been demonstrated to be by substantial evidence or substantial clinical experience, by selective presentation of information from published articles or other references that report no side effects or minimal side effects with the drug or otherwise selects information from any source in a way that makes a drug appear to be safer than has been demonstrated. (v) Presents information from a study in a way that implies that the study represents larger or more general experience with the drug than it actually does. (vi) Contains references to literature or studies that misrepresent the effectiveness of a drug by failure to disclose that claimed results may be due to concomitant therapy, or by failure to disclose the credible information available concerning the extent to which claimed results may be due to placebo effect (information concerning placebo effect is not required unless the advertisement promotes the drug for use …

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is a verbatim enumerated item under 21 CFR 202.1(e)(6), whose chapeau states that 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it:' — i.e., an operative per-se list, not an example, definition, or (e)(7) 'may be misleading' item. The rule statement ('may not be presented in a way implying it reflects broader or more general clinical experience than it actually represents') tracks the item's operative language without extension.
- Not overstated: the drafter correctly placed this in the mandatory (e)(6) list rather than the permissive (e)(7) list appearing later in the same source, so 'may not' rather than 'may be misleading' is faithful. No added scope beyond 'information from a study' as presented in an ad.
- Atomic: one checkable proposition — characterized scope vs. actual scope of a single study. It does not bundle in the neighboring but distinct prohibitions (e.g., (e)(6)(xiv) on pooled 'statistics', (e)(7)(i) on studies inadequate in design/scope).
- Determinism 'judgment' is correct: the provision turns on what the presentation 'implies', an impression-based test, and the rule's own escalation note ('a matter of degree') is consistent with that. No literal presence/absence test would settle it.
- Authority 'binding' is correct: 21 CFR 202.1 is a codified regulation implementing section 502(n) of the FD&C Act.
- Locator 21 CFR 202.1(e)(6)(v) matches the numbering in the source text exactly (item (v) within the (e)(6) enumeration).
- Severity 'blocker' is defensible: an advertisement meeting this description is, by the regulation's own terms, false/misleading and violative of 502(n), i.e., misbranding exposure rather than a stylistic defect.
- applies_when 'promotional' is justified — the provision governs prescription drug advertisements, which fall within promotional material. Note (not a required change given the available tags): the codified scope is prescription drug advertising specifically, and (e)(6) is subject to an FDA-granted written waiver on petition; neither undermines the rule as written for MLR review purposes.
- The check ('compare the study's actual scope/size/population to how it is characterized') is something a reviewer can actually perform against the study and the ad copy.